The global cardiac biomarkers market is anticipated to exhibit a growth of a CAGR of 11.3% between 2019 to 2027.
There are quite a few factors that drive the cardiac biomarkers market
such as the rising prevalence of hereditary diseases, the increasing elderly
population, etc.
ResearchMoz elucidates the detailed insights on the market including
market size, challenges, threats, opportunities, etc.
Detection of
Myocardial Infarction to Drive Cardiac Biomarkers Market
The rising incidences of myocardial infarction is expected to drive the
cardiac biomarkers market. Biomarkers such as Troponin can detect acute
myocardial infarction. Creatine Kinase MB and Troponin both can detect
early-stage acute myocardial infarction, leading to the growth of the global
cardiac biomarkers market.
Acute Coronary
Syndrome Segment to Boost the Demand
Acute Coronary Syndrome will increase the growth opportunities manifold
in the cardiac biomarkers market in the coming years. U.S alone registers,
nearly 780,000 cases of Acute Coronary Syndrome are registered each year,
paving the way for the cardiac biomarkers to grow in the coming years.
The high cost of testing is expected to hinder market growth in the
coming years.
Nevertheless, the high prevalence of cardiovascular diseases (CVDs) will
add to growth opportunities in the global cardiac biomarkers market over the
forecast years.
Analysts Views
Biomarkers that help in the diagnosis of cardiac diseases and provide
information about their effectiveness have a lot to offer. Different types of
biomarkers can diagnose different heart conditions, which is helpful. In
clinical practice, most commonly used markers are high-sensitivity cardiac
troponin, N-terminal pro B type natriuretic peptide and myoglobin but there is
always room for better ones as well alongside nanotechnologies to improve our
diagnostic techniques.
Early markers identified by enzymes sometimes also serve as diagnostics
helping with growth opportunities globally.
These biomarkers have been simplified over time with nanotechnologies
like electrochemiluminescence (ECL) and electrode chemistry, thus driving
growth for this market.
Regional Overview
The Asia Pacific region is projected to hold a lion’s share in the
cardiac biomarkers market during the forecast period, owing to the growing
prevalence of lifestyle-related disorders in this region. China is dominating
the Asia Pacific market, followed by Japan due to increasing cases of
cardiovascular diseases.
Competitive
Landscape
ResearchMoz shares a detailed report on the competitive landscape of
this market which would allow the new entrants to make informed decisions to
thrive in this space.
One of the key strategies companies use in the cardiac biomarkers market
is the acquisition of companies offering complementary products or services.
This allows them to capture other regional markets with their product offerings
and cater better to their customers.
The players in the market are –
- Thermo
Fisher Scientific Inc.
- bioMérieux
SA
- Hoffmann-La
Roche AG
- Abbott
- Siemens
AG
- Beckman
Coulter, Inc.
- Bio-Rad
Laboratories, Inc.
- Creative
Diagnostics
Get Free Sample PDF (Including Full TOC, Tables and Figures) of Market @
https://www.researchmoz.us/request-free-sample/?reportid=1467
No comments:
Post a Comment